BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol 2020;12:1758835920937612. [PMID: 32728392 DOI: 10.1177/1758835920937612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Annovazzi A, Ferraresi V, De Rimini ML, Sciuto R. 18F-FDG PET/CT in the clinical-diagnostic workup of patients treated with immunotherapy: when and how? Clin Transl Imaging. [DOI: 10.1007/s40336-022-00514-8] [Reference Citation Analysis]
2 Pfeiffer P, Qvortrup C, Hansen KH. How to select cancer patients for immunotherapy. EBioMedicine 2021;63:103184. [PMID: 33418504 DOI: 10.1016/j.ebiom.2020.103184] [Reference Citation Analysis]
3 Karapetyan L, Luke JJ, Davar D. Toll-Like Receptor 9 Agonists in Cancer. Onco Targets Ther 2020;13:10039-60. [PMID: 33116588 DOI: 10.2147/OTT.S247050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Bansal A, Pandey MK, Barham W, Liu X, Harrington SM, Lucien F, Dong H, Park SS, DeGrado TR. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nucl Med Biol 2021;100-101:4-11. [PMID: 34119742 DOI: 10.1016/j.nucmedbio.2021.05.004] [Reference Citation Analysis]
5 Gupta YH, Khanom A, Acton SE. Control of Dendritic Cell Function Within the Tumour Microenvironment. Front Immunol 2022;13:733800. [PMID: 35355992 DOI: 10.3389/fimmu.2022.733800] [Reference Citation Analysis]
6 Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther 2021;6:412. [PMID: 34897277 DOI: 10.1038/s41392-021-00823-w] [Reference Citation Analysis]
7 Lu M, Zhao B, Liu M, Wu L, Li Y, Zhai Y, Shen X. Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy. NPJ Precis Oncol 2021;5:51. [PMID: 34127768 DOI: 10.1038/s41698-021-00193-0] [Reference Citation Analysis]
8 Ying H, Zhang X, Duan Y, Lao M, Xu J, Yang H, Liang T, Bai X. Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacol Res 2021;170:105741. [PMID: 34174446 DOI: 10.1016/j.phrs.2021.105741] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 2021. [PMID: 34580473 DOI: 10.1038/s41571-021-00552-7] [Reference Citation Analysis]
10 Mann EK, Lee KJ, Chen D, da Silva LM, Dal Zotto VL, Scalici J, Gassman NR. Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response. Biology (Basel) 2021;10:385. [PMID: 33946684 DOI: 10.3390/biology10050385] [Reference Citation Analysis]
11 Zeng W, Li Z, Chen H, Zeng X, Mei L. An optimal portfolio of photothermal combined immunotherapy. Cell Reports Physical Science 2022. [DOI: 10.1016/j.xcrp.2022.100898] [Reference Citation Analysis]
12 Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, Pegliasco H, Le Treut J, Grisoni V, Coquet E, Chiche L, Rognon A. Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. Ther Clin Risk Manag 2021;17:669-77. [PMID: 34234443 DOI: 10.2147/TCRM.S308194] [Reference Citation Analysis]
13 Von Rueden SK, Fan TM. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Front Oncol 2021;11:773420. [PMID: 34869014 DOI: 10.3389/fonc.2021.773420] [Reference Citation Analysis]
14 Anaya-Ruiz M, Perez-Santos M. Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharm Pat Anal 2021. [PMID: 34875853 DOI: 10.4155/ppa-2021-0016] [Reference Citation Analysis]
15 Lu CH, Chung WM, Tsai CH, Cheng JC, Hsu KC, Tzeng HE. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction. Sci Rep 2022;12:303. [PMID: 34996924 DOI: 10.1038/s41598-021-03590-4] [Reference Citation Analysis]
16 Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Front Pharmacol 2021;12:790963. [PMID: 35002724 DOI: 10.3389/fphar.2021.790963] [Reference Citation Analysis]
17 Noto CN, Hoft SG, DiPaolo RJ. Mast Cells as Important Regulators in Autoimmunity and Cancer Development. Front Cell Dev Biol 2021;9:752350. [PMID: 34712668 DOI: 10.3389/fcell.2021.752350] [Reference Citation Analysis]
18 Ridge NA, Rajkumar-calkins A, Dudzinski SO, Kirschner AN, Newman NB. Radiopharmaceuticals as Novel Immune System Tracers. Advances in Radiation Oncology 2022. [DOI: 10.1016/j.adro.2022.100936] [Reference Citation Analysis]
19 Zhao B, Gao M, Zhao H, Zhao J, Shen X. Efficacy and safety profile of avelumab monotherapy. Crit Rev Oncol Hematol 2021;166:103464. [PMID: 34461272 DOI: 10.1016/j.critrevonc.2021.103464] [Reference Citation Analysis]
20 Ameli F, Shajareh E, Mokhtari M, Kosari F. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. BMC Cancer 2022;22:848. [PMID: 35922773 DOI: 10.1186/s12885-022-09803-x] [Reference Citation Analysis]
21 Zhang X, Wang Y, Xiang J, Zhao P, Xun Y, Zhang S, Xu N. Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer. J Int Med Res 2022;50:030006052210932. [DOI: 10.1177/03000605221093222] [Reference Citation Analysis]
22 Sun Z, Sun X, Chen Z, Du J, Wu Y. Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines. Int J Pept Res Ther 2022;28:19. [PMID: 34903958 DOI: 10.1007/s10989-021-10334-5] [Reference Citation Analysis]
23 Kannan S, O'Connor GM, Bakker EY. Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study. Int J Mol Sci 2021;22:5478. [PMID: 34067485 DOI: 10.3390/ijms22115478] [Reference Citation Analysis]
24 Rodrigues JG, Duarte HO, Reis CA, Gomes J. Aberrant protein glycosylation in cancer: implications in targeted therapy. Biochem Soc Trans 2021;49:843-54. [PMID: 33704376 DOI: 10.1042/BST20200763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zeng X, Zhong M, Yang Y, Wang Z, Zhu Y. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1 /CDK4 axis in non-small cell lung cancer. J Cell Mol Med 2021;25:4136-47. [PMID: 33630417 DOI: 10.1111/jcmm.16383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Watari N, Yamaguchi K, Masuda T, Ito N, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports. Thorac Cancer 2021;12:2956-60. [PMID: 34587368 DOI: 10.1111/1759-7714.14166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Naing A, Thistlethwaite F, De Vries EGE, Eskens FALM, Uboha N, Ott PA, LoRusso P, Garcia-Corbacho J, Boni V, Bendell J, Autio KA, Randhawa M, Durm G, Gil-Martin M, Stroh M, Hannah AL, Arkenau HT, Spira A. CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer 2021;9:e002447. [PMID: 34301809 DOI: 10.1136/jitc-2021-002447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022. [PMID: 35082367 DOI: 10.1038/s41571-022-00600-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 20.0] [Reference Citation Analysis]
30 De Beck L, Awad RM, Basso V, Casares N, De Ridder K, De Vlaeminck Y, Gnata A, Goyvaerts C, Lecocq Q, San José-Enériz E, Verhulst S, Maes K, Vanderkerken K, Agirre X, Prosper F, Lasarte JJ, Mondino A, Breckpot K. Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Front Immunol 2022;13:799636. [PMID: 35634329 DOI: 10.3389/fimmu.2022.799636] [Reference Citation Analysis]